FATE Company Profile and Key Details

Q: Who are the executives of FATE?

Dr. Bahram Valamehr Ph.D.Chief R&D OfficerMs. Cindy R. TahlGen. Counsel & Corporation Sec.Mr. Jim Beitel M.B.A.Senior Vice President of Corporation Devel.Mr. Edward J. Dulac IIIChief Financial OfficerDr. Mark Plavsic D.V.M., Ph.D.Chief Technical OfficerDr. Sarah CooleySenior Vice President of Clinical TranslationMr. Brian T. Powl M.B.A., M.S.Chief Commercial OfficerDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityMr. J. Scott WolchkoFounder, Chief Executive Officer, Pres & DirectorDr. Yu-Waye Chu M.D.Chief Medical Officer

NASDAQ : FATE

Fate Therapeutics

$1.14

0.04+3.64%

Open: 3:28 PM

58.9

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Fate Therapeutics, Inc. (FATE) stock surged +3.64%, trading at $1.14 on NASDAQ, up from the previous close of $1.10. The stock opened at $1.13, fluctuating between $1.11 and $1.17 in the recent session.

Stock Snapshot

1.1

Prev. Close

131.5M

Market Cap

1.105

Day Low

-0.86

P/E Ratio

-1.33

EPS (TTM)

-1.4

Cash Flow per Share

1.13

Open

115.35M

Number of Shares

1.17

Day High

87.4%

Free Float in %

3.74

Book Value

1.19M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	1.17	1.19	1.10	1.10	1.92M
Jan 16, 2026	1.04	1.22	1.04	1.19	5.11M
Jan 15, 2026	1.07	1.09	1.03	1.05	1.06M
Jan 14, 2026	1.03	1.09	1.03	1.08	1.49M
Jan 13, 2026	1.07	1.08	1.02	1.02	1.44M
Jan 12, 2026	1.07	1.08	1.03	1.07	1.91M
Jan 09, 2026	1.06	1.09	1.04	1.05	1.26M
Jan 08, 2026	1.11	1.12	1.04	1.06	1.45M
Jan 07, 2026	1.02	1.13	1.02	1.11	2.19M
Jan 06, 2026	1.00	1.06	1.00	1.01	1.54M
Jan 05, 2026	0.99	1.02	0.97	1.01	1.27M
Jan 02, 2026	0.99	1.01	0.97	0.99	966.7K
Dec 31, 2025	0.99	1.00	0.97	0.98	810.22K
Dec 30, 2025	0.98	1.00	0.96	0.98	1.23M
Dec 29, 2025	1.00	1.02	0.98	1.00	1.08M
Dec 26, 2025	1.00	1.02	0.98	1.00	991.76K
Dec 24, 2025	1.00	1.03	1.00	1.01	791.53K
Dec 23, 2025	1.06	1.07	0.95	0.98	3.58M
Dec 22, 2025	1.06	1.10	1.05	1.05	1.21M
Dec 19, 2025	1.05	1.12	1.03	1.05	2.83M

Contact Details

San Diego, CA 92131

United States

https://www.fatetherapeutics.com 858 875 1800

About Company

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Fate Therapeutics, Inc. (FATE) stock price?

Fate Therapeutics, Inc. (NASDAQ: FATE) stock price is $1.14 in the last trading session. During the trading session, FATE stock reached the peak price of $1.17 while $1.11 was the lowest point it dropped to. The percentage change in FATE stock occurred in the recent session was 3.64% while the dollar amount for the price change in FATE stock was $0.04.

FATE's industry and sector of operation?

The NASDAQ listed FATE is part of Biotechnology industry that operates in the broader Healthcare sector. Fate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FATE?

Dr. Bahram Valamehr Ph.D.
Chief R&D Officer
Ms. Cindy R. Tahl
Gen. Counsel & Corporation Sec.
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporation Devel.
Mr. Edward J. Dulac III
Chief Financial Officer
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technical Officer
Dr. Sarah Cooley
Senior Vice President of Clinical Translation
Mr. Brian T. Powl M.B.A., M.S.
Chief Commercial Officer
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Mr. J. Scott Wolchko
Founder, Chief Executive Officer, Pres & Director
Dr. Yu-Waye Chu M.D.
Chief Medical Officer

How FATE did perform over past 52-week?

FATE's closing price is 66.67% higher than its 52-week low of $0.66 where as its distance from 52-week high of $1.94 is -43.3%.

How many employees does FATE have?

Number of FATE employees currently stands at 181.

Link for FATE official website?

Official Website of FATE is: https://www.fatetherapeutics.com

How do I contact FATE?

FATE could be contacted at phone 858 875 1800 and can also be accessed through its website. FATE operates from 12278 Scripps Summit Drive, San Diego, CA 92131, United States.

How many shares of FATE are traded daily?

FATE stock volume for the day was 1.19M shares. The average number of FATE shares traded daily for last 3 months was 1.71M.

What is the market cap of FATE currently?

The market value of FATE currently stands at $131.50M with its latest stock price at $1.14 and 115.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	181
Beta	2.23
Sales or Revenue	$63.53M
5Y Sales Change%	6.654%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	181
Beta	2.23
Sales or Revenue	$63.53M
5Y Sales Change%	6.654%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FATE Company Profile and Key Details

Fate Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook